Selecting molecular therapeutic drug targets based on the expression profiles of intrahepatic cholangiocarcinomas and miRNA-mRNA regulatory networks

Sun,Boshi; Xie,Changming; Zheng,Tongsen; Yin,Dalong; Wang,Jiabei; Liang,Yingjian; Li,Yuejin; Yang,Guangchao; Shi,Huawen; Pei,Tiemin; Han,Jihua; Liu,Lianxin

doi:10.3892/or.2015.4330

Selecting molecular therapeutic drug targets based on the expression profiles of intrahepatic cholangiocarcinomas and miRNA-mRNA regulatory networks

Authors:
- Boshi Sun
- Changming Xie
- Tongsen Zheng
- Dalong Yin
- Jiabei Wang
- Yingjian Liang
- Yuejin Li
- Guangchao Yang
- Huawen Shi
- Tiemin Pei
- Jihua Han
- Lianxin Liu
View Affiliations

Affiliations: Key Laboratory of Hepatosplenic Surgery, Chinese Ministry of Education, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: October 15, 2015 https://doi.org/10.3892/or.2015.4330
Pages: 382-390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of intrahepatic cholangiocarcinoma (ICC) is increasing yearly, making it the second most common carcinoma after hepatocellular carcinoma among primary malignant liver tumors. Integrated miRNA and mRNA analysis is becoming more frequently used in antitumor ICC treatment. However, this approach generates vast amounts of data, which leads to difficulties performing comprehensive analyses to identify specific therapeutic drug targets. In this study, we provide an in-depth analysis of ICC function, identifying potential highly potent antitumor drugs for antitumor therapy. Two sets of whole genome expression profiles were obtained from the Gene Expression Omnibus (GEO) database. Using modular bioinformatic analysis, six core functional modules were identified for ICC. Based on a Fisher's test of the Cmap small molecule drug database, 65 drug components were identified that regulated the genes of these six core modules. Literature mining was then used to identify 15 new potential antitumor drugs.

View Figures

View References

1	Francis H, Alpini G and DeMorrow S: Recent advances in the regulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol. 299:G1–G9. 2010. View Article : Google Scholar : PubMed/NCBI
2	Tyson GL and El-Serag HB: Risk factors for cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E and Alvaro D: Cholangiocarcinoma: Update and future perspectives. Dig Liver Dis. 42:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
4	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mavros MN, Economopoulos KP, Alexiou VG and Pawlik TM: Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg. Apr 9–2014.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
6	Zhou H, Wang H, Zhou D, Wang H, Wang Q, Zou S, Tu Q, Wu M and Hu H: Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer. 46:1056–1061. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sulpice L, Rayar M, Boucher E, Pele F, Pracht M, Meunier B and Boudjema K: Intrahepatic cholangiocarcinoma: Impact of genetic hemochromatosis on outcome and overall survival after surgical resection. J Surg Res. 180:56–61. 2013. View Article : Google Scholar
8	Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF and Pawlik TM: Intrahepatic cholangiocarcinoma: Management options and emerging therapies. J Am Coll Surg. 217:736–750.e4. 2013. View Article : Google Scholar : PubMed/NCBI
9	Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai Q, Ke H, Levey AI, Li L and Chin LS: Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem. 279:8506–8515. 2004. View Article : Google Scholar
10	Maita C, Maita H, Iguchi-Ariga SM and Ariga H: Monomer DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants. PLoS One. 8:e540872013. View Article : Google Scholar : PubMed/NCBI
11	Shah SP, Lonial S and Boise LH: When cancer fights back: Multiple myeloma, proteasome inhibition, and the heat-shock response. Mol Cancer Res. 13:1163–1173. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yoo HM, Park JH, Jeon YJ and Chung CH: Ubiquitin-fold modifier 1 acts as a positive regulator of breast cancer. Front Endocrinol (Lausanne). 6:362015.
13	Wan J, Zhan J, Li S, Ma J, Xu W, Liu C, Xue X, Xie Y, Fang W, Chin YE, et al: PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression. Nucleic Acids Res. 43:3591–3604. 2015. View Article : Google Scholar : PubMed/NCBI
14	Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, et al: Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 9:643–651. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, Deng Y, Yang Y, Li Y, Ruan X, et al: Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget. 6:20636–20649. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ling J, Jiang L, Zhang C, Dai J, Wu Q and Tan J: Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells. In Vitro Cell Dev Biol Anim. 51:835–842. 2015. View Article : Google Scholar : PubMed/NCBI
17	Güllü G, Peker I, Haholu A, Eren F, Küçükodaci Z, Güleç B, Baloglu H, Erzik C, Özer A and Akkiprik M: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. Genet Mol Biol. 38:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kavalieris L, O'Sullivan PJ, Suttie JM, Pownall BK, Gilling PJ, Chemasle C and Darling DG: A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol. 15:232015. View Article : Google Scholar : PubMed/NCBI
19	Huang Y, Shen P, Chen X, Chen Z, Zhao T, Chen N, Gong J, Nie L, Xu M, Li X, et al: Transcriptional regulation of BNIP3 by Sp3 in prostate cancer. Prostate. 75:1556–1567. 2015. View Article : Google Scholar : PubMed/NCBI
20	Jiang K, Wang W, Jin X, Wang Z, Ji Z and Meng G: Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells. Oncol Rep. 33:2711–2718. 2015.PubMed/NCBI
21	Cherigo L, Lopez D and Martinez-Luis S: Marine natura products as breast cancer resistance protein inhibitors. Mar Drugs. 13:2010–2029. 2015. View Article : Google Scholar : PubMed/NCBI
22	Van Bael K, Jansen Y, Seremet T, Engels B, Delvaux G and Neyns B: A case report of long-term survival following hepatic arterial infusion of L-folinic acid modulated 5-fluorouracil combined with intravenous irinotecan and cetuximab followed by hepatectomy in a patient with initially unresectable colorectal liver metastases. Case Rep Oncol Med. 2015:4720372015.
23	Hayashi H, Beppu T, Sakamoto Y, Miyamoto Y, Yokoyama N, Higashi T, Nitta H, Hashimoto D, Chikamoto A and Baba H: Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am J Cancer Res. 5:1225–1233. 2015.PubMed/NCBI